Monopar to Present at the 35th Annual Roth Conference
Monopar Therapeutics (Nasdaq: MNPR), a biopharmaceutical company dedicated to cancer therapeutics, announced that CEO Chandler Robinson will participate in a fireside chat at the 35th Annual Roth Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Monopar Therapeutics (Nasdaq: MNPR), a biopharmaceutical company dedicated to cancer therapeutics, announced that CEO Chandler Robinson will participate in a fireside chat at the 35th Annual Roth Conference.
Event Details:
Date: March 13, 2023
Time: 12:30-1:00 pm PT
Location: The Ritz Carlton, Laguna Niguel, Dana Point, California.
Monopar's pipeline includes Validive® (Phase 2b/3) for severe oral mucositis, camsirubicin (Phase 1b) for soft tissue sarcoma, and MNPR-101 & MNPR-202 for advanced cancers. For more information, visit www.monopartx.com.
Details
News Market Reaction – MNPR
The recorded move for MNPR in the trading session of this news was -1.00%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WILMETTE, Ill., March 07, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will participate in a fireside chat at the 35th Annual Roth Conference.
Presentation Details:
Date: March 13, 2023
Time: 12:30-1:00 pm Pacific Time
Location: The Ritz Carlton, Laguna Niguel in Dana Point, California
https://www.roth.com/conferences/upcoming-conferences
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive® (Phase 2b/3) for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for radiopharmaceutical use in advanced cancers; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information, visit: www.monopartx.com.
CONTACT:
Monopar Therapeutics Inc.
Investor Relations
Kim R. Tsuchimoto
Chief Financial Officer
kimtsu@monopartx.com
Follow Monopar on social media for updates:
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.